This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Galapagos/AbbVie CF Corrector, GLPG-2222
Galapagos/AbbVie CF Corrector is a novel cystic fibrosis (CF) compound that defects in expression of (corrector) the main mutations in the cystic fibrosis transmembrane regulator (CFTR) protein, including the F508del and G551D mutation.
The compound will be tested in combination with the potentiator (GLPG1837), which is being developed as part of the Galapagos/AbbVie CF program.
AbbVie and Galapagos
In September 2013, AbbVie and Galapagos announced a collaboration to develop potentiators and correctors discovered by Galapagos and expand that range of molecules. Following successful clinical development and regulatory approval, AbbVie will be responsible for commercial activities, with Galapagos retaining exclusive rights in China and South Korea and co-promotion rights in Belgium, the Netherlands, and Luxembourg.
Under the terms of the agreement, AbbVie will make an initial upfront payment of $45 million to Galapagos for rights related to the global alliance. Upon successful completion of pre-determined success milestones, AbbVie and Galapagos will share responsibility and funding for Phase III clinical development. Galapagos is eligible to receive up to $360 million in total additional payments for developmental and regulatory milestones, sales milestones upon the achievement of minimum annual net sales thresholds and additional...See full deal structure in Biomedtracker
Partners: Galapagos NV
Additional information available to subscribers only: